Skip to content

BeiGene in licensing deal for neutralizing COVID-19 antibodies

August 27, 2020

BeiGene (NASDAQ:BGNE) and Singlomics (Beijing DanXu) Biopharmaceuticals have executed an exclusive license agreement for BeiGene to develop, manufacture and commercialize globally ex-China, the latter’s investigational anti-COVID-19 antibodies, including DXP-593 and DXP-604.

Under the terms of the agreement, Singlomics will receive an upfront payment and be eligible to receive milestone payments and tiered royalties, up to double digits, on future product sales.

Phase 1 and Phase 1/2 clinical trials are expected to begin enrollment of healthy subjects and patients with mild to moderate COVID-19 in September and early October, respectively.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: